Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398538 | 0.85 | CA1 (0.67) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL17791098 | 0.82 | — | — | |
| SCHEMBL16398588 | 0.81 | CA1 (0.62) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL20529627 | 0.81 | CA1 (1.00) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL16398233 | 0.80 | CA1 (0.63) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL16398580 | 0.80 | CA1 (0.63) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL17791100 | 0.79 | CA1 (0.51) | CA1CA2CA9 | |
| SCHEMBL16408375 | 0.79 | — | — | |
| SCHEMBL16398460 | 0.79 | — | — | |
| SCHEMBL29919009 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| EP-3022175-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | CA1 598/4885CA2 109/4885CA9 797/4885 |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN5A | CA1 598/4885CA2 109/4885CA9 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.